Gut health startup The Good Bug raises Rs 100 Cr in Series B round

Gut health startup The Good Bug has raised Rs 100 crore (about $12 million) in a Series B funding round led by Susquehanna Asia Venture Capital, the VC arm of Susquehanna International Group, along with participation from its existing investor, Fireside Ventures.

Prior to this, the Mumbai-based startup had raised $4 million in a Series A extension in 2024, led by Sharrp Ventures, the family office of Marico Group’s Harsh Mariwala. The latest fundraise brings its total funding to around $20 million.

The proceeds will be used to ramp up R&D in microbiome science, scale clinical trials, expand distribution, and strengthen brand awareness among both consumers and healthcare professionals, The Good Bug said in a press release.

Co-founded in 2022 by Keshav Biyani and Prabhu Karthikeyan, The Good Bug develops probiotic and gut-focused health products targeting digestion, immunity, and metabolic health. The startup recently introduced Metabolically Lean, a GLP-1-based formulation marketed as a natural, non-invasive alternative to weight-loss drugs like Ozempic and Mounjaro. The brand claims the product naturally boosts GLP-1 levels to curb appetite and improve metabolism.

“The main deployment of these funds will be towards accelerating innovation in microbiome science and bacterial research.” We’ll continue investing in clinical trials, brand building, and hiring top-tier talent across research, science, and business,” said Keshav Biyani, co-founder of The Good Bug.